724 related articles for article (PubMed ID: 26705102)
1. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
2. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.
Moschini M; Sharma V; Dell'oglio P; Cucchiara V; Gandaglia G; Cantiello F; Zattoni F; Pellucchi F; Briganti A; Damiano R; Montorsi F; Salonia A; Colombo R
BJU Int; 2016 Apr; 117(4):604-10. PubMed ID: 25851271
[TBL] [Abstract][Full Text] [Related]
3. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
[TBL] [Abstract][Full Text] [Related]
4. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome.
Turker P; Bostrom PJ; Wroclawski ML; van Rhijn B; Kortekangas H; Kuk C; Mirtti T; Fleshner NE; Jewett MA; Finelli A; Kwast TV; Evans A; Sweet J; Laato M; Zlotta AR
BJU Int; 2012 Sep; 110(6):804-11. PubMed ID: 22321341
[TBL] [Abstract][Full Text] [Related]
5. Delays in radical cystectomy for muscle-invasive bladder cancer.
Chu AT; Holt SK; Wright JL; Ramos JD; Grivas P; Yu EY; Gore JL
Cancer; 2019 Jun; 125(12):2011-2017. PubMed ID: 30840335
[TBL] [Abstract][Full Text] [Related]
6. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
[TBL] [Abstract][Full Text] [Related]
7. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
8. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study.
Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW
Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469
[TBL] [Abstract][Full Text] [Related]
9. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
10. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
11. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
Lane G; Risk M; Fan Y; Krishna S; Konety B
BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
[TBL] [Abstract][Full Text] [Related]
12. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
13. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
14. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands.
Hinsenveld FJ; Boormans JL; van der Poel HG; van der Schoot DKE; Vis AN; Aben KKH; Arends TJ; Ausems PJ; Baselmans D; Berger C; Berrens A; Bickerstaffe H; Bos SD; Braam M; Buddingh KT; Claus S; Dekker K; van Doeveren T; Einerhand S; Fossion L; van Gennep EJ; van Ginkel N; Palacios G; Hermans T; Hobijn MM; van Huystee SH; Jaspers-Valentijn M; Klaver OS; Koldewijn EL; Korsten L; Lenting A; Lentjes KJ; Luiting HB; van der Meer S; Nieuwenhuijzen JA; Noordzij MA; Nooter RI; Notenboom C; Oomen R; van Roermund J; de Rooij J; Roshani H; Schrier BP; van der Slot MA; Somford DM; Stelwagen PJ; Stroux A; van der West A; Wijsman BP; Windt W; van Zanten P; van Beek SC;
Urol Oncol; 2022 Feb; 40(2):60.e1-60.e9. PubMed ID: 34303597
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.
Seisen T; Sun M; Lipsitz SR; Abdollah F; Leow JJ; Menon M; Preston MA; Harshman LC; Kibel AS; Nguyen PL; Bellmunt J; Choueiri TK; Trinh QD
Eur Urol; 2017 Oct; 72(4):483-487. PubMed ID: 28412065
[TBL] [Abstract][Full Text] [Related]
17. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
18. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients.
Koga F; Kihara K; Yoshida S; Yokoyama M; Saito K; Masuda H; Fujii Y; Kawakami S
BJU Int; 2012 Mar; 109(6):860-6. PubMed ID: 21854531
[TBL] [Abstract][Full Text] [Related]
19. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
20. Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume.
Goossens-Laan CA; Visser O; Hulshof MC; Wouters MW; Bosch JL; Coebergh JW; Kil PJ
BJU Int; 2012 Jul; 110(2):226-32. PubMed ID: 22044615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
